Introduction
Invasive aspergillosis (IA) remains an important complication in hematopoietic stem cell (HSCT) and solid organ voriconazole as the initial drug of choice for IA, while combination antifungal therapy is not recommended for initial therapy [9] . Although the impact of specifi c antifungal therapies on effi cacy and mortality has been studied in transplant patients, few data are available from investigations of combination antifungal therapy. Moreover, the importance of antifungal drugs and use of combination antifungal therapy in relation to economic outcomes is an area of increased interest [4, 7, 12, 13] . From a database of prospectively identifi ed cases of IA, part of the Transplant Associated Infection Surveillance Network (TRANSNET), we describe antifungal treatment practices for IA and factors associated with hospital length-of-stay, an important measure of healthcare utilization.
Materials and methods
TRANSNET is a Center for Diseases Control and Prevention and industry co-sponsored prospective surveillance network comprised of 23 US transplant centers that has been described previously [6,14 -16] [17] . For this study, nine sites submitted additional antifungal treatment and hospital length-of-stay data on previously enrolled patients. This information was requested and collected retrospectively after the initial data collection for the study. Sites were included if they had enrolled at least 15 patients with proven or probable IA in the initial study and were willing to participate in the current investigation. Of a total of 652 IA cases from TRANSNET, 361 are described herein. This study was approved by the Institutional Review Board of all participating institutions and informed consent was obtained where dictated by the participating institution.
Clinical data and defi nitions
Demographics, transplant type, underlying diseases, site(s) of IA, and etiologic Aspergillus species data were collected. Treatment data included drug(s) and duration of therapy. For the purposes of this study, primary combination therapy was defi ned as the administration of two antiAspergillus antifungals as initial therapy within 48 hours of IA diagnosis. Salvage therapy was defi ned as substitution for or addition of another antifungal at any time during the treatment course, after the use of the initial antifungal(s). Neutropenia was defi ned as an absolute neutrophil count (ANC) Ͻ 500/mm 3 within 30 days of diagnosis of IA, representing pre-or post-engraftment secondary neutropenia. CMV infection or disease was defi ned as CMV detected in blood (antigen, PCR), or histopathologic evidence of CMV, in association with signs and symptoms consistent with infection. Graft-versus-host disease (GVHD) was considered positive if grade Ͼ II, as defi ned by site investigator. The following defi nitions of co-morbid conditions were applied at the time of diagnosis of IA: renal insufficiency as a creatinine Ն 3.0 mg/dl or a creatinine clearance Ͻ 30 ml/min; corticosteroid use as any systemic use; hepatic insuffi ciency as ascites, other clinical stigmata of liver disease, or abnormal laboratory values (prothrombin time, INR, liver enzyme tests); malnutrition as a serum albumin Ͻ 2 g/dl or Յ 5% ideal body weight if albumin between 2.1 -2.5g/dl. Early-onset IA was defi ned as diagnosis Ͻ 30 days post-transplantation. Disseminated IA was defi ned as extrapulmonary disease, excluding sinus disease. Mold-active antifungal prophylaxis was defi ned as receipt of any systemic agent in the 3 months prior to diagnosis of IA, excluding use for empiric or pre-emptive therapy. The primary outcome endpoint was hospital length-of-stay, measured as proportion of patients with length-of-stay greater than 30 days. Crude mortality was determined at 6-and 12-weeks post-diagnosis of IA.
Statistical analysis
Descriptive statistics were calculated for demographic and clinical characteristics, as well as for antifungal therapies. The primary outcome measure was length of stay, categorized as less than 30 days or 30 days and greater. To minimize the competing risk of death and impact of death on length of stay, patients included in the multivariable analyses must have survived at least 30 days. Unadjusted logistic regression analyses were performed to examine individual associations between demographic, clinical, and treatment variables and length of stay for patients who lived at least 30 days after IA diagnosis. Stepwise multiple logistic regression analyses were performed to examine factors associated with length of stay (as a dichotomous variable). Variables signifi cant at α ϭ 0.20 in univariate analyses were considered as possible predictor variables for multivariable analyses. The criterion for entry into the model was signifi cance at α ϭ 0.20, whereas the criterion for remaining in the model was signifi cance at α ϭ 0.05. Age, gender, race, transplant type (HSCT or SOT), hospital (site), and either combination therapy or initial voriconazole therapy were included in every model. Variables that were allowed to enter or exit the model included: neutropenia, CMV disease, renal insuffi ciency, hepatic insufficiency, malnutrition, prednisone use, methylprednisone use, disseminated disease, and ICU stay. The fi nal model was obtained by including terms selected through the stepwise an AmB formulation plus caspofungin (22/361, 6.1%). Overall, fewer patients who received initial combination therapy had a change in antifungal regimen when compared to those who received initial single drug therapy (33/128, 25.8% vs. 144/233, 61.8% ; P Ͻ 0.001). The most common change was discontinuation of voriconazole plus caspofungin and start of LFAmB.
Mean length of therapy after IA diagnosis, available for 357 patients, was 115 days (HSCT 109.7; SOT 125.3) . Among patients who survived at least six weeks, the mean length of therapy was 162.1 days. Six-week mortality was similar among patients who received initial single (30.6%) or combination therapy (28.8%) and lower than in patients who received any salvage therapy (40%). Mortality by initial drugs received by the patients was similar, i.e., voriconazole (31.7%), caspofungin (29.1%), AmB preparation (26.2%), or itraconazole (35.7%).
Factors associated with length-of-stay
Analyses of factors associated with LOS Ն 30 days were performed among 234 patients who survived at least 30 days and univariate analyses can be found in Table 3 . For the multivariable analyses, two models were constructed (Table 4) , i.e., the fi rst analysis included antifungal strategy (initial combination versus monotherapy) in addition to co-morbidities and demographic factors. It was found that using multivariable logistic regression that neutropenia (OR 3.41; P ϭ 0.007), malnutrition (OR 2.83; P ϭ 0.02), disseminated IA (OR 3.2; P ϭ 0.02) and length of ICU stay (OR 1.14; P Ͻ 0.001) were associated with increased length of stay. In contrast, combination antifungal therapy (OR 0.47; P ϭ 0.062) was associated with decreased LOS but it was not significant. A sensitivity analysis (not shown) was performed with use of multivariable linear regression in patients who survived at least 14 days, with the dependent variable being length of stay (days). Model results were nearly identical, except combination therapy was associated with a statistically signifi cant reduction in length of stay ( P ϭ 0.03).
The second multivariable analysis differed only in that it included specifi c initial antifungal use (voriconazole versus other antifungals) instead of antifungal strategy in the model. Initial voriconazole use (OR 0.41; P ϭ 0.027) and prednisone use (OR 0.41; P ϭ 0.043) were signifi cantly associated with decreased LOS. In contrast, neutropenia (OR 3.05; P ϭ 0.016), malnutrition (OR 2.82; P ϭ 0.037) and length of ICU stay (OR 1.12; P Ͻ 0.001) were associated with increased length of stay.
Discussion
Management of invasive aspergillosis in HSCT and SOT patients remains challenging. This analysis of a subgroup procedure (and terms that were forced into every model) alone. As a sensitivity analysis, unadjusted linear regression analyses and stepwise multiple linear regression analyses were performed. In these analyses, the outcome measure was length of stay as a continuous variable. The results obtained were similar to those found through the logistic regression analyses. Statistical tests were twosided and were performed using a 5% signifi cance level ( α ϭ 0.05). Statistical analyses were performed using SAS, version 9.2 (SAS Institute). (Table 1) Of 652 IA patients enrolled in TRANSNET during the study period, 361 from nine TRANSNET sites were included to evaluate the performance of antifungal therapy for IA and factors associated with hospital length-of-stay. Mean age of patients was 49 years, 60.7% were male, 89.5% were Caucasian and 63% were HSCT recipients. Aspergillosis was classifi ed as proven in 101 (28%) cases. Mean time to development of IA post-transplant was 378.6 days, with the mean hospital length-of-stay (LOS) of 35.3 days (HSCT 38.7; SOT 29.7) and mean ICU LOS of 7.6 days (HSCT 5.1; SOT 11.8). Six-week all-cause mortality was 31.8% (HSCT 36.4%; SOT 24.1%). The most common SOT was lung (48.1%) and the most common HSCT was allogeneic from a matched related donor (35.5%). Common co-morbidities in the population included diabetes (39.3%), neutropenia (34.1%), renal insuffi ciency (34.1%) and CMV disease (26.6%) ( Table 1) . (Table 2) Forty-eight different regimens were employed to treat IA. Primary monotherapy was most common and used with 233 (64.5%) of the 361 patients. For patients who received monotherapy, voriconazole was the most frequent initially administered (93/233, 39.9%) antifungal, followed by a lipid formulation of amphotericin B (LFAmB) (78/233, 33.5%). A total of 144 (61.8%) patients had a change in antifungal regimen after initial monotherapy (single salvage), most often caspofungin was added to voriconazole. The percentage of patients receiving a change in therapy was similar for patients receiving voriconazole (59.1%), LFAmB (55.1%) or itraconazole (59.1%); but was higher for patients who received initial caspofungin (78.5%) or AmB deoxycholate (87.5%). No data were available regarding reasons for changes in therapy. Initial combination antifungal therapy was used with 128 (35.5%) of 361 patients, with the most frequent combination being voriconazole plus caspofungin (81/361, 22.4%), followed by of the TRANSNET database describes antifungal therapy for IA and impact on hospital length-of-stay, both of which may have important economic implications.
Results

Patient characteristics
Antifungal therapy
The development of newer antifungal agents in the past decade has provided more potential options for effective therapy, including oral treatment. Predictably, this has led to some confusion as to the best approaches for treatment. Indeed, among our cohort, 48 different regimens were employed, underscoring the complexity and lack of uniformity in the approach to treating transplant patients with IA. The 2008 IDSA guidelines for the treatment of aspergillosis recommend voriconazole as the drug of choice for primary IA for most patients [8, 9] . While a number of agents were used as primary therapy in our series of transplant patients, voriconazole and AmB were the most common, which is consistent with the 2008 IDSA guidelines. Our study demonstrated that in a small group of US transplant patients, use of combination therapy is not uncommon, despite lack of evidenced-based support from randomized trials. The most frequent regimen administered was voriconazole plus caspofungin or LFAmB plus caspofungin. Fewer patients who received primary combination therapy were subject to modifi cations in their therapy defi ned by starting or adding an antifungal drug, when compared to those with primary monotherapy. The reasons for this increased ' durability ' of combination regimens in our study is unclear, but could be related to effi cacy or safety issues, or the fact that people starting combination therapy may just have fewer options for subsequent treatment. Data on reason for changing therapy were not collected as part of this study but this issue requires more investigation.
Duration of therapy for IA is related to a number of factors, including extent of disease, level of immunosuppression, resolution of lesions and availability of medication that can be administered easily to those in the inpatient or outpatient setting. Although the 2008 IDSA guidelines recommend therapy to be continued for 6 -12 weeks, the duration among our patients was more prolonged (mean of 115 days). This difference is probably the result of the level of immunosuppression of the patients and the severity of illness associated with IA in transplant patients. Our data may be of use in formulating future guidelines on length of therapy in clinical practice.
While there is an increased interest in the economic implications of invasive fungal infections, the impact of factors related to hospital LOS for IA patients has not been well characterized [4,5,7,12,13,18 -20] . Most studies compare LOS in patients with or without aspergillosis and, as expected, patients with aspergillosis have prolonged hospital or intensive care unit LOS [4, 13, 18, 20] . Our investigation identifi ed several factors associated with hospital LOS, including treatment-related issues which are under the control of healthcare practitioners.
First, neutropenia, malnutrition, disseminated IA and prolonged ICU LOS were associated with increased LOS. As expected, most of these are markers of severity of illness and would result in prolonged hospital stays. Second, use of voriconazole as part of the initial antifungal regimen was associated with reduced LOS after controlling for multiple co-morbidities. The effect of antifungal agents on LOS was evaluated recently by Kim and colleagues, who analyzed the Premier Perspective Database to determine hospital outcomes and costs associated with aspergillosis [4] . They reported that voriconazole, amphotericin B lipid complex and caspofungin were associated with decreased LOS, whereas voriconazole was associated with reduced hospital costs [4] . In our study, only voriconazole was associated with decreased LOS and this may be related to availability of an oral formulation, allowing potential early discharge.
In our primary analysis, combination therapy (when compared to single therapy) was not signifi cantly associated with decreased LOS (OR 0.47; P ϭ 0.062). In the sensitivity analysis (linear regression), where the sample size was larger, this fi nding was signifi cant. Theoretically, if combination therapy results in better clinical response, then perhaps patients may be discharged from the hospital earlier.
Our study did not measure clinical response, but mortality was not statistically different between single versus combination therapy groups. Our primary analysis may have been underpowered to fully evaluate combination therapy.
Our study has several limitations. Since only a subgroup of the TRANSNET dataset was used, it may affect external validity. Discharge criteria were dictated by individual sites and may have led to variability in length of stay. For this reason, site was included in the fi nal multivariable models and did not impact the results. Finally, it is possible that confounding variables were not added to the multivariable models, or that small frequencies of some variables would not allow for a more thorough statistical evaluation. For example, status of underlying malignancy was not available as a variable for HSCT patients.
In conclusion, among this cohort of transplant patients with IA, voriconazole or AMB preparations were employed frequently as initial therapy and use of primary combination therapy was common. Duration of therapy for transplant patients with IA was prolonged. Specifi c initial antifungal therapy (voriconazole versus other) impacts LOS, but the majority of factors associated with hospital LOS are surrogates of patient severity of illness. Further work evaluating the economic impact of antifungal therapy in patients with IA is needed. For personal use only.
